Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Buy rating reiterated by Wedbush with a $36.00 price target

Analyst Ratings For Allena Pharmaceuticals Inc (NASDAQ:ALNA)

Story continues below

Today, Wedbush reiterated its Buy rating on Allena Pharmaceuticals Inc (NASDAQ:ALNA) with a price target of $36.00.

There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Allena Pharmaceuticals Inc (NASDAQ:ALNA) is Buy with a consensus target price of $24.60 per share, a potential 407.22% upside.

Some recent analyst ratings include

  • 7/2/2019-Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Buy rating reiterated by Wedbush with a $36.00 price target
  • 5/10/2019-Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Buy rating reiterated by Cowen
  • 1/18/2019-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Outperform ➝ Outperform rating and $20.00 price target
  • 11/8/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy rating and $22.00 price target
  • 8/2/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy rating and $23.00 price target
  • 4/2/2018-Allena Pharmaceuticals Inc (NASDAQ:ALNA) has coverage initiated with a Buy ➝ Buy rating and $61.00 price target
  • On 11/6/2017 Bessemer Venture Partners Vii, Major Shareholder, bought 36,000 with an average share price of $14.00 per share and the total transaction amounting to $504,000.00.
  • On 11/6/2017 James N Topper, Director, bought 500,000 with an average share price of $14.00 per share and the total transaction amounting to $7,000,000.00.

About Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. Read More…

Recent Trading Activity for Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Shares of Allena Pharmaceuticals Inc closed the previous trading session at 4.85 up +0.35 7.78% with 146272 shares trading hands.

An ad to help with our costs